• Erqi L Pollom, Dylann Fujimoto, Jacob Wynne, Kira Seiger, Leslie A Modlin, Lisa R Jacobs, Melissa Azoulay, Rie von Eyben, Laurie Tupper, Iris C Gibbs, Steven L Hancock, Gordon Li, Steven D Chang, John R Adler, Griffith R Harsh, Ciara Harraher, Seema Nagpal, Reena P Thomas, Lawrence D Recht, ChoiClara Y HCYHDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, California; Department of Radiation Oncology, Santa Clara Valley Medical Center, San Jose, California., and Scott G Soltys.
• Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
• Int. J. Radiat. Oncol. Biol. Phys. 2017 May 1; 98 (1): 123-130.

PurposeWe report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide.MethodsHRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point.ResultsWith a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01).ConclusionOn this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL.Copyright © 2017 Elsevier Inc. All rights reserved.

43 keywords...

hide…